Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Accountable Care Organizations
- Alternative Payment Models
- Biopharmaceutical Innovation
- Bundled Payments
- Clinical Pathways
- Decision Frameworks
- Elements of Value
- Evidence for Decision Making
- (-) Formulary/Benefit Design
- Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- (-) Health Spending
- Health Spend Management
- High-Deductible Health Plans
- (-) Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- IRA Implementation
- Low-Value Care
- Pandemic Response
- Patient Cost Sharing
- Paying for Cures
- Policy & Regulatory Barriers
- Real-World Data
- Real-World Evidence
- Regulatory Barriers & Challenges
- (-) Understanding Health Spending
- Utilization Management & Step Therapy
- Value-Based Contracts
- Value-Based Insurance Design
- Value Assessment
- Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Display Only
Showing 214 Results
A Healthier Country Means Lower Health Care Spending
The U.S. spends twice as much per person on health care compared to other wealthy countries. While higher U.S. health care prices play a role in this disparity, they are not the only cause. A new NPC…
It Is Not Just the Prices! The Role of Chronic Disease in Accounting for Higher Health Care Spending in the United States
A new NPC study shows that the higher prevalence of chronic disease in the U.S. is a significant contributing factor to high U.S. health care spending.
Drug Innovations Are Delivering for Patients. We Need Innovation in How They’re Paid For.
In a commentary for PharmaBoardroom, NPC's John M. O’Brien explains why we need a focused effort from all health care stakeholders to innovate on how we pay for vital medicines.
Rethinking Benefit Design: Eliminating Inefficient Hurdles
Reforming health benefits by overhauling existing utilization management practices and adjusting patient cost-sharing to incentivize high-value care would help achieve more affordable, patient…
Building a Better Evidence Base to Address the Social Determinants of Health
The COVID-19 pandemic has put a spotlight on the pressing need to address social determinants of health (SDOH). NPC's Dr. Dubois examines the gaps within the existing evidence base and how…
Why Drug Rebates Aren’t Working for Patients
During a recent webinar, NPC President and CEO John M. O'Brien discusses how the Medicare Part D rebate system creates barriers to affordable care for patients.
Do Investments in the Social Determinants of Health Reduce Health Care Costs?
This study found that most studies of social need interventions were poorly designed, inadequately documented, and inconsistently presented. It recommends improving the study design quality through…
Limited Role of Patient Input in Specialty Drug Coverage Policies
A new study in JMCP found that patient input is rarely sought for coverage policies – although plans had processes to engage physicians and medical societies when developing coverage policies, no…
Missing: Patient Input in Drug Coverage Policy
A new study by NPC and the Center for the Evaluation of Value and Risk in Health at Tufts Medical Center found that health insurance plans do not ask patients for input when developing specialty drug…
NPC in Morning Consult: Biopharmaceutical Price Regulation - No Panacea for Patients
In a column published in Morning Consult, NPC's research team explains why potential government involvement in drug pricing would be unlikely to increase patient affordability.
What the Data Are Saying on Drug Pricing and Utilization
NPC President and CEO John O'Brien discusses the IQVIA Institute’s new report and takes a closer look at the factors that are driving medication use and health care spending in the United States.
Affordability Is About More Than Drug Prices
A research survey found that potential government involvement in drug pricing would be unlikely to increase patient affordability.
Affordability Is About More Than Drug Prices
A research survey from NPC and Xcenda found that potential government involvement in drug pricing would be unlikely to increase patient affordability.
Celebrating the Use of Medicines in Keeping People Healthy
NPC President and CEO John O'Brien discusses how prescription medicines and the pharmacists who provided them helped people stay healthy at home during the pandemic.
The Budget Cap Dilemma: Can You Reduce Spending and Preserve Patient Health?
National Pharmaceutical Council (NPC) hosted a virtual panel discussion on state decisions to implement budget caps and the strategies, challenges, and the relevance of these decisions on patient…
Focus on Whole Person Quality Care When Implementing Budget Caps
The National Pharmaceutical Council hosted a virtual panel discussion on state decisions to implement budget caps and the strategies, challenges, and the relevance of these decisions on patient…
Savvy Employers Alter Status Quo to Address Drugs, Deductibles and Disincentives for Treatment
Thanks to an IRS rule, high-deductible health plans with health savings accounts can now cover an expanded list of preventive services and drugs before patients meet their plan’s annual out-of-pocket…
Health Budgets Should Cap Patient Harm
An NPC-RTI study provides guidance on quality metrics and practices that can help decision makers understand which budget cap features have the potential to lessen the impact on patient health and…
AMCP Partnership Forum: Preparing for and Managing Rare Diseases
Stakeholders met virtually for an AMCP Partnership Forum to discuss viable solutions to challenges facing people living with rare disorders, such as affordable and timely access to therapies,…
The Dollar or Disease Burden: Caps on Healthcare Spending May Save Money, but at What “Cost” to Patients?
This study assessed the potential effects of budget caps design on disease burden and cost savings to help budget decision makers understand which budget cap features minimize impact to patient…